| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
22072 |
| Drug |
Eladocagene exuparvovec |
| Brand |
Upstaza® |
| Indication |
For the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype. |
| Rapid review commissioned |
08/12/2022 |
| Rapid review completed |
23/12/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of eladocagene exuparvovec compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/02/2023 |
| Pre-submission consultation with Applicant |
18/04/2023 |
